Arxis is an electronic trading firm specializing in the automated market-making of global securities. Its goal is to develop and utilize technological innovations that intelligently analyze data in order to deliver liquidity across asset classes.
Quentin Chu is a partner and member of the Investment Committee. He is a leader of Crestview's investments in financial services as well as other sectors.
Quentin Chu joined Crestview in July 2005 after graduating from Harvard Business School. He is a partner of the firm and a member of the Investment Committee. Prior to HBS, Quentin was an associate at The Carlyle Group, where he evaluated and executed transactions in the healthcare industry, including pharmaceuticals, medical devices, facility-based providers, managed care and outsourcing. Prior to joining Carlyle, Quentin was an analyst in the healthcare investment banking team at Goldman Sachs, where he completed a range of M&A and financing assignments for both early stage and Fortune 500 companies. Quentin is currently a director of Arxis Capital Group and a board observer at Capital Bank and Oxbow Carbon. Quentin also serves on the board of Breakthrough New York. Quentin received an M.B.A. from Harvard Business School, and an A.B., summa cum laude, in classics from Harvard College, where he was elected to Phi Beta Kappa.
Capital Bank Financial is a bank holding company that was established by Crestview and management in 2009. As of March 31, 2017, it has acquired eight banks and has $10.1 billion in assets with over 190 branches throughout the southeast.
Lancashire is a global provider of specialty insurance and reinsurance, focusing on short-tail risks in property, energy, marine, aviation and Lloyd’s. The company was established in 2005.
Munder is an investment advisory firm offering actively managed investment products to institutional and retail clients. It offers a broad array of equity, fixed income and balanced investment disciplines and was acquired by Victory Capital in October 2014.
Oxbow Carbon engages in the global sourcing, production, marketing and distribution of refinery byproducts and solid carbon fuel, including fuel grade petroleum coke, calcined petcoke, sulfur, activated carbon and coal.
PartnerRe is a global multi-line reinsurer specialized in property and casualty, life and health and alternative risk products. Crestview initially invested in Paris Re (formerly AXA Re) in 2006, which subsequently merged with PartnerRe in 2009.
Prior to its acquisition by Surgery Partners in November 2014, Symbion owned and operated a national network of short-stay surgical facilities across many specialties.